Denali Therapeutics (DNLI) Free Cash Flow (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Free Cash Flow data on file, last reported at -$133.7 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 2.11% year-over-year to -$133.7 million in Q1 2026; TTM through Mar 2026 was -$419.2 million, a 13.41% decrease from a year earlier, with the FY2025 full-year figure at -$422.1 million, down 20.99% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$133.7 million, down from -$109.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for DNLI reached as high as -$49.7 million in Q2 2022 and fell as low as -$136.5 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$89.4 million across 5 years, with a median of -$83.7 million in 2024.
• Across the five-year window, Free Cash Flow sank 132.77% in 2023 and soared 32.19% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$72.4 million in 2022, then tumbled by 54.18% to -$111.6 million in 2023, then gained by 24.97% to -$83.7 million in 2024, then tumbled by 30.59% to -$109.3 million in 2025, then dropped by 22.25% to -$133.7 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$133.7 million in Q1 2026, -$109.3 million in Q4 2025, and -$96.6 million in Q3 2025.